Please provide your email address to receive an email when new articles are posted on . Discontinuation of denosumab is associated with a rapid return to pretreatment BMD levels and an increased risk ...

The researchers found that 6.3, 6.6, and 11.1% of the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo groups, respectively, had a new morphometric fracture at follow-up. HealthDay ...

Please provide your email address to receive an email when new articles are posted on . “The need to establish treatment efficacy in osteopenia has become more pressing, given the clinical trend to ...

MESSINA, Italy — Although the bisphosphonate zoledronic acid, or zoledronate (Aclasta, Reclast, Novartis), stops bone loss in patients with osteoporosis, it also ups levels of the protein biomarker ...

June 7, 2011 (Boston, Massachusetts) — Lower doses than are currently prescribed of the bisphosphonate zoledronate may be enough to increase bone density and reduce bone resorption in postmenopausal ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...

BACKGROUND: Intravenous zoledronate 5 mg annually reduces fracture risk, and 5 mg every 2 years prevents bone loss, but the optimal dosing regimens for these indications are uncertain. METHODS: We ...

To counter the decline in BMD after denosumab treatment is discontinued, osteoporosis patients may be transitioned from denosumab to other anti-resorptives. This report investigates whether a single ...

Joo Hwan No, Fernando de Macedo Dossin, Yonghui Zhang, Yi-Liang Liu, Wei Zhu, Xinxin Feng, Jinyoung Anny Yoo, Eunhae Lee, Ke Wang, Raymond Hui, Lucio H. Freitas-Junior, Eric Oldfield Proceedings of ...